Michelle Gershberg

Michelle Gershberg, Global Health Editor at Reuters, dives into the rapidly evolving world of weight-loss drugs, once confined to Hollywood, now a global sensation. She discusses the surge in popularity of semaglutide and trisepatide, their transition from diabetes drugs to weight loss staples, and the pressing issue of affordability. Gershberg also sheds light on the disparities in insurance coverage and the recent Biden administration policies on weight-loss medication access. The conversation unpacks both the promise and controversies surrounding these treatments.

Caroline Humer, U.S. Health and Pharma editor, and Michelle Gershberg, Global Health editor, dive into Robert F. Kennedy Jr.'s proposed cuts to major health agencies like the FDA and CDC. They discuss the potential fallout from reducing approximately 10,000 jobs and how this could affect the country’s readiness for health threats like measles outbreaks. The conversation highlights industry reactions, concerns over leadership changes impacting drug approvals, and the risk posed by rising vaccine hesitancy among families.